v3.26.1
Other Receivable, Net - Schedule of Other Receivable (Details) - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Other Receivablesnet    
Loan receivable [1] $ 14,355,283
Proceeds receivable from sale of subsidiary [2] 2,416,086
Other 559 94,074
Other receivables, net $ 16,771,928 $ 94,074
[1] During the year ended December 31, 2025, the Company entered into five borrowing arrangements with a third party for an aggregate principal amount of $14,160,101, bearing interest at 9% per annum. Certain borrowings were guaranteed by individuals or entities or secured by certain assets. As of December 31, 2025, the aggregate accrued and unpaid interest related to these borrowings was $195,182.
[2] There was $2,416,086 receivable from the sale of the Company’s subsidiary, SYCI, which is due in 2026 from Shandong Rongyuan Pharmaceutical Co., Ltd.